Co-encapsulation of IroN and IL-12 as an Extra-intestinal E. coli Vaccine.

IroN 和 IL-12 共封装作为肠外大肠杆菌疫苗。

• 批准号: 7394780
• 负责人: Thomas F Conway
• 金额: $ 29.25万
• 依托单位: THERAPYX, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-15 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7394780
• 关键词: Address; Adjuvant; Animals; Antibiotic Resistance; Antibodies; Antibody Formation; Antigens; Area; Avian Influenza; Bacterial Infections; Biological; Bladder; CD4 Positive T Lymphocytes; Cancer Vaccines; Cellular Immunity; Cessation of life; Communicable Diseases; Complement; Development; Dose; Drug Formulations; Economics; Encapsulated; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Frequencies; Generations; Goals; Growth; Healthcare; Immune; Immune Sera; Immune response; Immune system; Immunity; Immunization; In Vitro; Infection; Infection prevention; Infectious Agent; Interferons; Interleukin-12; Intestines; Iron; Kidney; Life; Localized; MF59; Marketing; Measures; Mediating; Medical Economics; Modeling; Mus; Organism; Particulate; Patients; Phase; Phase I Clinical Trials; Prevention; Property; Prophylactic treatment; Public Health; Published Comment; QS21; Refrigeration; Route; Saliva; Salts; Sepsis; Serum; Severities; Staining method; Stains; Standards of Weights and Measures; System; T-Lymphocyte; Technology; Temperature; Testing; Toxicity Tests; Urinary tract infection; Urine; Vaccinated; Vaccination; Vaccine Adjuvant; Vaccine Antigen; Vaccine Production; Vaccines; Viral; Work; World Health; aluminum sulfate; antimicrobial; bactericide; base; cytokine; design; nanoparticle; neutrophil; new technology; novel; pathogen; pathogenic Escherichia coli; response

DESCRIPTION (provided by applicant): Despite recent advances in the treatment and prevention of infectious disease, the threat to world health continues to grow. The spread of new zoonotic viral strains like avian influenza and the emergence of antibiotic resistant forms of long established pathogens such E. coli underscores the danger from ever evolving pathogens. In this era of expanding infectious threats, the development of novel, effective and practical vaccine adjuvants has lagged considerably. Adjuvants can be classified as 1) delivery systems or 2) immune potentiators on the basis of their mechanism of action. Immune potentiators, such as cytokines, activate the immune system directly. Delivery system adjuvants serve to concentrate or target vaccine antigens to APCs or to co-localize antigens and immune potentiators. TherapyX, Inc. uses the proprietary phase inversion nanoencapsulation (PIN) technology to create biological adjuvants that combine the properties of an immune potentiator and a delivery system. To this end, TherapyX, Inc. has developed a particulate-based, sustained-release cytokine adjuvant formulation that can induce highly effective TH1 type T-cell and antibody responses. Proof of principle for the efficacy of this formulation has been demonstrated in numerous tumor vaccine studies. More recently, TherapyX, Inc. developed a second generation nanoparticle formulation (TPX-506) that is biologically stable at room temperature for at least one year; making this an ideal adjuvant for vaccination against infectious disease in underdeveloped areas of the world. This application will test the efficacy of TPX-506 against extraintestinal pathogenic Escherichia coli (ExPEC) in a mouse urinary tract infection model. The diversity, frequency, potential severity, and economic impact of extraintestinal infections due to E. coli are as great as for any bacterial infection. With no other current vaccines available, the successful production this vaccine will address a significant gap in the bacterial prophylaxis market. PUBLIC HEALTH RELEVANCE - PROJECT NARRATIVE: The diversity, frequency, potential severity, and economic impact of extraintestinal infections due to E. coli are as great as for any bacterial infection. This application will test the efficacy of the TPX-506 vaccine against extraintestinal pathogenic Escherichia coli (ExPEC) infection. With no other current vaccines available, the successful production this vaccine will address a significant gap in the bacterial prophylaxis market.

描述（申请人提供）：尽管治疗和预防传染病的最新进展，但对世界卫生的威胁仍在增长。新的人畜共患病毒菌株（如鸟类流感）的传播以及长期建立的病原体的抗生素耐药形式的出现强调了不断发展的病原体所带来的危险。在这个不断扩大的传染性威胁时代，新颖，有效和实用的疫苗佐剂的发展已大大落后。可以将佐剂分类为1）输送系统或2）根据其作用机理的免疫增强剂。免疫增强剂（例如细胞因子）直接激活免疫系统。递送系统佐剂用于将抗原浓缩或靶向APC或共定位抗原和免疫增强剂。 Therapyx，Inc。使用专有阶段反转纳米封装（PIN）技术来创建结合免疫增强剂和输送系统特性的生物佐剂。为此，Therapyx，Inc。开发了一种基于颗粒的，持续释放的细胞因子辅助配方，可以诱导高效的Th1 T型T细胞和抗体反应。在众多肿瘤疫苗研究中已经证明了该配方功效的原理证明。最近，Therapyx，Inc。开发了第二代纳米颗粒配方（TPX-506），该配方在室温下至少在生物学上稳定至少一年。这是世界欠发达地区疫苗接种传染病的理想佐剂。该应用将测试TPX-506对小鼠尿路感染模型中肠外致病性大肠杆菌（EXPEC）的功效。大肠杆菌引起的肠外感染的多样性，频率，潜在的严重程度和经济影响与任何细菌感染一样大。由于没有其他当前的疫苗可用，该疫苗的成功生产将解决细菌预防市场的显着差距。 公共卫生相关性 - 项目叙述：大肠杆菌引起的肠外感染的多样性，频率，潜在严重性和经济影响与任何细菌感染一样大。该应用将测试TPX-506疫苗对肠外致病性大肠杆菌（EXPEC）感染的功效。由于没有其他当前的疫苗可用，该疫苗的成功生产将解决细菌预防市场的显着差距。